EyeCRO scientists contribute to paper published in Biology
Therapeutic Effects of Fenofibrate Nano-Emulsion Eye Drops on Retinal Vascular Leakage and Neovascularization
Similar Posts
Retinal Ischemia Tied to Variant of Acute Macular Neuroretinopathy
Paracentral acute middle maculopathy is a newly identified variant of acute macular neuroretinopathy that appears to result from retinal capillary ischemia, according to a retrospective observational case series. “This has been traditionally a very rare disease but now with advanced retinal imaging systems such as spectral domain optical coherence tomography (SD-OCT) and infrared reflectance imaging…
eyecro’s First Published Article in Molecular and Cellular Biology
Retinol-Binding Protein 4 Induces Inflammation in Human Endothelial Cells by a NADPH Oxidase- and Nuclear Factor Kappa B-dependent and Retinol-Independent Mechanism Krysten M. Farjoa,#, Rafal A. Farjob, Stacey Halseya, Gennadiy Moiseyeva and Jian-xing Maa aDepartment of Physiology, University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma beyecro LLC, Oklahoma City, Oklahoma ABSTRACT Serum retinol-binding protein…
Scientists find a way to ‘shrink’ blind spot in human eye
The optic nerve that sends visual signals to the brain must pass through the retina which creates a hole in that light-sensitive layer of tissue. When images project to that precise location, we miss them. This blind spot can be ‘shrunk’ despite the fact that the hole in our visual field cannot be. The findings…
MiDROPS® Achieves Clinical Safety and Efficacy Milestone
EyeCRO is thrilled to announce the first clinical application of our groundbreaking MiDROPS® technology.
Data Monitoring Committee Recommends Continuation of APOLLO Phase 3 Clinical Trial of Patisiran for Hereditary ATTR Amyloidosis with Polyneuropathy (hATTR-PN)
CAMBRIDGE, Mass.–(BUSINESS WIRE)– Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY), the leading RNAi therapeutics company, announced today that the Data Monitoring Committee (DMC) for the Phase 3 APOLLO study of patisiran in patients with hereditary ATTR amyloidosis with polyneuropathy (hATTR-PN) met on October 7, 2016 and recommended continuation of the trial without modification. Read the entire article here.
New Age-Related Macular Degeneration Common in Untreated Fellow Eyes
“NEW YORK (Reuters Health) – New age-related macular degeneration (AMD) develops in about a quarter of fellow eyes to those treated for neovascular AMD with intravitreal anti-VEGF agents, according to a post hoc analysis of the VIEW 1 and VIEW 2 studies.” “The high risk for fellow eye conversion in patients with neovascular AMD in…